Application to Clinical Study Results
The age-specific reference ranges established by Oesterling's group have been applied retrospectively to a number of studies and have substantiated the contention that this PSA index increases sensitivity among younger men and specificity among older men. In one study of 2,998 men more than 60 years of age from a single urologic practice, age-specific reference ranges decreased sensitivity by 9% but increased specificity by 11% and positive predictive value by 5%. If these reference ranges had been used, 92 biopsies (5.5%) would have been avoided, and only 19 (.6%) cancers would not have been detected. However, of these 19 cancers, 13 were detected in men ³ 70 years of age and 18 were unlikely to be of clinical consequence, based on organ confinement, tumor volume, and Gleason grade.
Partin and colleagues reviewed the records of 4,597 men with clinically localized prostate cancer from the extensive Johns Hopkins surgical series. Using the standard reference PSA value of 4.0 ng/mL alone, they found that 82% of tumors would have been detected; age-specific reference ranges would have detected 78%. Age-specific reference ranges would have found 18% more cancers in men less than 60 years of age and 22% fewer cancers in men 60 years of age or more.
In men less than 60 years of age, 74 cancers would have been detected by age-specific reference ranges but not by the standard reference. Moreover, of these 74 cancers, 60 (81%) had a favorable pathologic status: either organ confinement or capsular penetration with a Gleason grade of less than 7. In men 60 years of age or more, 252 tumors would not have been detected, but of these tumors, 76% (191) had a favorable pathologic status. This study concluded that age-specific reference ranges are most useful in men 60 years of age or more with T1c prostate cancer (ie, they increase specificity) because 95% of the "missed" tumors among older men had a favorable pathologic status.
Another study, apparently based on results from early detection programs, concurred that age-specific reference ranges increased sensitivity in detecting prostate cancer in younger men, who would be more likely to benefit from treatment, while decreasing the biopsy rate in older patients. These investigators concluded that age-specific reference ranges would be most valuable for patients more than 70 years of age, among whom 22% would have been spared transrectal ultrasonography with biopsy. Similarly, Lankford and colleagues found a significant association between PSA levels and age (r = .33) and a significant improvement in specificity when age-specific reference ranges were applied to men 70 years of age or more , as compared with the standard PSA reference (58.6% and 34.2%, respectively).
Two European studies[42,43] reported results based on the application of age-specific reference ranges to findings from screening populations. Reissigl and associates reported that an 8% increase in biopsies among younger men (in their 40s and 50s) would have occurred with age-specific reference ranges, but this would have effected an 8% increase in the detection of organ-confined cancer. In older men (more than 60 years), 21% fewer biopsies would have been performed and 4% of organ-confined tumors would have been missed. Using age-specific reference ranges and digital rectal examination as indicators for biopsy, Bangma and colleagues reported that a 37% reduction in biopsies would have occurred, with a 12% loss of detected cancers, all of which were nonpalpable and organ-confined .
Although these studies generally support the use of age-specific reference ranges to improve the characteristics of PSA testing, they do not provide sufficient evidence for their universal application. The variability of findings likely reflects the diagnostic capabilities of the clinical investigators, the detection technologies employed, and the different patient populations. One autopsy study confirmed an increased specificity with age-specific reference ranges among men more than 60 years of age, but such studies simply show that cancers are missed and an elevated PSA value (more than 4.0 ng/mL) alone does not indicate cancer.
Criticisms of Age-Specific Ranges
Widespread acceptance of age-specific PSA reference ranges as a valuable index for the effective and efficient detection of prostate cancer has been compromised by negative clinical findings, philosophy, and the continued adequate performance of the standard reference PSA value of 4.0 ng/mL. Age-specific reference ranges have theoretical appeal, but study results are not consistent with regard to the percentage and type of prostate cancers not detected among older men when age-specific reference ranges have been applied retrospectively.
Data from the American Cancer Society's National Prostate Cancer Detection Project showed that age-specific reference ranges increased specificity but at a nonsignificant loss of sensitivity. A PSA value of 4.0 ng/mL alone had a sensitivity of 71.9% and a specificity of 90%; age-specific reference ranges had a sensitivity of 67.3% and a specificity of 90.9%.
A German study concluded that the application of age-specific reference ranges (or any PSA value less than 3.1 ng/mL) does not improve the test's sensitivity among men younger than age 50. Moreover, using a higher PSA value (7.5 ng/mL) for men more than 70 years of age does improve specificity but lowers sensitivity.
Although Oesterling and colleagues and Partin's group each noted that only 5% of cancers undetected with age-specific reference ranges had unfavorable histology, a recent study reported that 60% (9 of 15) of cancers that would have remained undetected by age-specific reference ranges had histologic characteristics qualifying them as large, life-threatening, and clinically significant. All of these cancers were in men younger than age 75.
In another extensive critique of age-specific reference ranges, Catalona and associates concluded that if an age-specific reference of 3.5 ng/mL had been used for men between the ages of 50 and 59, there would have been a 45% increase in biopsies, with only a projected 15% increase in cancer detection. If an age-specific reference of 4.5 ng/mL had been used for men between the ages of 60 and 69, 15% fewer biopsies would have occurred, but 8% of organ-confined tumors would have been missed. Increasing the normal PSA cut-off value to 6.5 ng/mL for men more than 70 years would have resulted in 44% fewer biopsies (70 of 159) and would have missed 47% of detected organ-confined cancers (7 of 15). This study concluded that a PSA value of 4.0 ng/mL need not be altered for older men because the number of biopsies performed for each cancer detected remained constant across age groupings, apparently unaffected by the simultaneously increasing prevalence of BPH and cancer with age.
In light of the fact that both sensitivity and specificity cannot be improved simultaneously, the philosophical issue surrounding age-specific reference ranges is whether sensitivity or specificity should take priority. Advocates of screening and early detection of prostate cancer favor sensitivity over specificity because more clinically important, organ-confined disease will be detected. In fact, it has been proposed that the threshold for normal be lowered from 4.0 to 2.5 ng/mL for everyone. A more provocative proposal has been to ignore PSA values and age-specific reference ranges completely and simply to perform a biopsy on all men at 50 years of age; specificity would be sacrificed at the altar of universal detection.
These and similar proposals may not be implemented because of the relatively satisfactory performance of a single demarcation between normal and elevated PSA levels. The reference for the maximum normal PSA value (4.0 ng/mL) was established with a population mix younger than would be normally tested for prostate cancer: 472 individuals, of whom only 55 were between the ages of 50 and 59 and 19 were 60 years of ageor more. This basis may not reflect the increasing risk of prostate cancer with increasing age, but the objective was to identify a demarcation between normal and elevated PSA levels. Unless another standard becomes more acceptable, the imperfect nature of the PSA test may simply require such a norm; ie, below 4.0 ng/mL to detect more organ-confined cancers regardless of the higher number of false-positive results or above 4.0 ng/mL to detect fewer clinically insignificant cancers while missing more clinically significant cancers.
Variations on the Age-Specific Reference Range Theme
Attempts to complement the value of age-specific reference ranges in the detection of prostate cancer have included consideration of prostatic volume after age-specific reference ranges and proposed volume-referenced PSA values. Meshref and colleagues studied PSA density with age-specific reference ranges. In a clinically referred population (N = 2,429), transrectal ultrasonography was performed on everyone. This experience alone indicated proficiency in establishing comparable estimations of volume and led to the finding that volume is more strongly correlated to PSA value (r = .46) than are PSA values to age (r = .25). Prostate-specific antigen density (which directly relates serum PSA values to prostatic volume), however, showed a weak correlation with age (r = .1).
In multiple regression analysis, prostate volume accounted for 18% of the variation in serum PSA values, whereas age accounted for only an additional 2%. In the patient group with PSA values between the age-specific upper limit of normal and 10.0 ng/mL, the positive rate of biopsy in patients with a PSA density less than .15 was only 1.9% (2/108/315), but in patients with a PSA density more than .15, the positive rate of biopsy was 27.2% (59/217/240). This study concluded: (1) that age-specific reference ranges do not totally account for the effect of prostate volume on serum PSA values and (2) that PSA density can still safely be used to reduce the number of biopsies performed in patients with a normal digital rectal examination and transrectal ultrasonography, as well as a serum PSA level 10.0 ng/mL or less but above the age-specific reference range limit of normal.
Babaian and associates also attempted to address the mixed results of studies of PSA density and age-specific reference ranges. Because the association of glandular volume with PSA values is stronger than that with age, these investigators developed the concept of volume-referenced PSA testing and compared its sensitivity and specificity with other indices.
Volume-referenced PSA testing was more sensitive but less specific than age-specific reference ranges and PSA density; it was only equivalent to PSA testing clinically. Age-specific reference ranges would have prevented more biopsies than volume-referenced testing (39% vs 31%) but would have resulted in the diagnosis of 48% fewer cancers. Receiver-operator characteristic curve analysis demonstrated a better performance for volume-referenced PSA testing and PSA density than for PSA testing or age-specific reference ranges.
In the PSA value range of 4 to 10 ng/mL, volume-referenced testing was superior to PSA testing (P = less than .01) and age-specific reference ranges (P less than .001) and equivalent to PSA density. In this range, age-specific reference ranges missed the fewest cancers (6%) but resulted in the fewest biopsies (12%). However, a key point of this study was that enhanced detection of prostate cancer was inversely associated with increasing volume of the prostate gland and directly related to increasing patient age.
The relationship between age-specific reference ranges and PSA change--PSA velocity--offers another potential PSA index that could improve the test's characteristics. Pearson and colleagues studied annual PSA velocity rates in 727 men (age range, 35 to 92 years) with no history of prostate cancer and a PSA level < 10 ng/mL. The mean PSA velocity and the upper limits of PSA velocity increased significantly with age (P less than .001). Age-specific values for PSA velocity were suggested: less than 50 years of age, 0.125 ng/mL/yr; 50 to 59 years old, 0.15 ng/mL/yr; 60 to 69 years old, 0.3 ng/mL/yr; and 70 years older more, 0.4 ng/mL/yr.
The shortcoming of this study, however, is the particular PSA range of values selected (ie, 4.0 to 10.0 ng/mL) to establish age-specific PSA velocity: Whatever range of PSA values is used to establish "normal" PSA velocity will directly influence the resultant PSA velocity determinations. If, for example, a PSA value of 0.0 to 4.0 ng/mL is used to establish PSA velocity levels, the age-specific rates will be much lower. Again, it becomes a question of whether to emphasize sensitivity or specificity in the detection of prostate cancer by using age-specific PSA velocity values.
1. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
2. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368, 1994.
3. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985.
4. Cohen P, Peehl DM, Lamson G, et al: Insulin-like growth factors (IGFs), IGF receptors, and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401-407, 1991.
5. Cohen P, Graves HCB, Peehl DM, et al: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053, 1992.
6. Christensson A, Laurell C-B, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763, 1990.
7. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of human prostate-specific antigen. Invest Urol 17:159-163, 1979.
8. Qui S-D, Young CY, Bilhartz DL, et al: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144:1550-1556, 1990.
9. Schmid H-P, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. Cancer 71:2031-2040, 1993.
10. Stamey TA, Yang N, Hay AR, et al: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
11. Smith DS, Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45:70-75, 1995.
12. Littrup PJ, Kane RA, Mettlin CJ, et al: Cost-effective prostate cancer detection: Reduction of low-yield biopsies: The investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 74:3077-3079, 1994.
13. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
14. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845, 1992.
15. Labrie F, Dupont A, Suburu R, et al: Serum prostate specific antigen: A prescreening test for prostate cancer. J Urol 147:846-852, 1992.
16. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 151:1283-1290, 1994.
17. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989.
18. Richie JP, Catalona WJ, Ahmann FR, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42:365-374, 1993.
19. Begg CB: Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. Semin Oncol 21:569-579, 1994.
20. Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147:817-821, 1992.
21. Kalish J, Cooner WH, Graham Jr SD: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43:601-606, 1994.
22. Carter HB, Pearson JD: PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 20:665-670, 1993.
23. Lilja H: Significance of different molecular forms of serum PSA: The free, noncomplexed form of PSA versus that complexed to a1-antichymotrypsin. Urol Clin North Am 20:681-686, 1993.
24. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995.
25. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993.
26. Seaman E, Whang M, Olsson CA, et al: PSA density (PSAD): Role in patient evaluation and management. Urol Clin North Am 20:653-663, 1993.
27. Jewett MAS, Jain U, Toi A, et al: Prostate specific antigen density (PSAD): Can it distinguish between benign hyperplasia and malignancy (abstract)? J Urol 149:415A, 1993.
28. Brawer MK, Aramburu FAG, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150:369-373, 1993.
29. Babaian RJ, Kojima M, Ramierez EI, et al: Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 156:432-437, 1996.
30. Collins GN, Lee RJ, McKelvie GB, et al: Relationship between prostate specific antigen, prostate volume, and age in the benign prostate. Br J Urol 71:445-450, 1993.
31. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
32. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed, and total serum prostate specific antigen: The establishment of appropriate reference ranges for the concentrations and ratios. J Urol 154:1090-1095, 1995.
33. Babaian RJ, Miyashita H, Evans RB, et al: The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age. J Urol 147:837-840, 1992.
34. Oesterling JE: The importance of patient age and race in establishing appropriate reference ranges for serum PSA. Proceedings from the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris, France, June 22-24, 1994.
35. Oesterling JE: Using prostate-specific antigen to eliminate unnecessary diagnostic tests: Significant worldwide economic implications. Urology 46(suppl 3A):26-33, 1995.
36. Dalkin BL, Ahmann FR, Kopp JB: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837-1839, 1993.
37. DeAntoni EP, Crawford ED, Oesterling JE, et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48:234-239, 1996.
38. Oesterling JE, Jacobsen SJ, Cooner WH: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153:1160-1163, 1995.
39. Partin AW, Criley SR, Subong ENP, et al: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 155:1336-1339, 1996.
40. El-Galley RES, Petros JA, Saunders WH, et al: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 46:200-204, 1995.
41. Lankford SP, Peters KL, Elser RC: Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol 27:182-186, 1995.
42. Reissigl A, Pointer J, Horninger W, et al: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening study. Urology 46:662-665, 1995.
43. Bangma CH, Kranze R, Blijenberg BG, et al: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46:779-784, 1995.
44. Speights Jr VO, Brawn PN, Foster DM, et al: Evaluation of age-specific normal ranges for prostate-specific antigen. Urology 45:454-458, 1995.
45. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 74:1615-1620, 1994.
46. Weichert-Jacobsen K, Tilmann L: Clinical significance of prostate specific antigen age-specific reference ranges. J Urol 153:465A, 1995. Abstract.
47. Borer JG, Sherman J, Solomon MC, et al: Age-specific reference ranges for prostate specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures. J Urol 155:322A, 1996. Abstract.
48. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2037-2042, 1994.
49. Catalona WJ, Smith DS: Comparison of different serum prostate specific antigen measures for early prostate cancer detection (editorial). Cancer 74:1516-1518, 1994.
50. Catalona WJ: What to do when the PSA is 'abnormal.' Proceedings from the American Urological Association Meeting, Orlando, Florida, May 6, 1996.
51. Fleming C, Barry MJ, Oesterling JE: Prostate-specific antigen (PSA) age-specific reference ranges versus a single threshold: Is the best answer to bypass PSA and biopsy everyone (abstract)? J Urol 155:452A, 1996.
52. Petteway J, Brawer MK: Age specific vs 4.0 ng/mL as a PSA cutoff in the screening population: Impact on cancer detection (abstract). J Urol 153:465A, 1995.
53. Myrtle JF, Klimley PG, Ivor LP, et al: Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer, in Advances in Cancer Diagnostics. San Diego, Hybritech, Inc., 1986.
54. Meshref AW, Bazinet M, Trudel C, et al: Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology 45:972-979, 1995.
55. Pearson JD, Carter HB, Metter EJ, et al: Sensitivity and specificity of age-specific reference ranges for PSA velocity (abstract). J Urol 153:465A, 1995.
56. Anderson JR, Strickland D, Corbin D, et al: Age-specific reference ranges for serum prostate-specific antigen. Urology 46:54-57, 1995.
57. Nadler RB, Humphrey PA, Smith DS, et al: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407-413, 1995.